A66 is an inhibitor of p110? PI3K that exhibits anticancer chemotherapeutic activity. A66 decreases cell viability of endometrial cancer cells and inhibits tumor growth of xenografts when administered in combination with other therapies. In animal models, A66 increases glucose output and impairs glucose and insulin tolerance.
Uniformity of Dosage Units
Allschoolabs
Uniformity of Dosage Units is a specialised analytical laboratory service that assesses whether individual dosage units contain sufficiently consis...



































